PE20070171A1 - GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa - Google Patents

GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa

Info

Publication number
PE20070171A1
PE20070171A1 PE2006000745A PE2006000745A PE20070171A1 PE 20070171 A1 PE20070171 A1 PE 20070171A1 PE 2006000745 A PE2006000745 A PE 2006000745A PE 2006000745 A PE2006000745 A PE 2006000745A PE 20070171 A1 PE20070171 A1 PE 20070171A1
Authority
PE
Peru
Prior art keywords
thiofen
carbonylamine
azepin
benzo
tetrahydro
Prior art date
Application number
PE2006000745A
Other languages
English (en)
Inventor
Henning Priepke
Georg Dahmann
Roland Pfau
Annette Schuler-Metz
Herbert Nar
Sandra Handschuh
Wolfgang Wienen
Kai Gerlach
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20070171A1 publication Critical patent/PE20070171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DE GLICINAMIDA SUSTITUIDAS DE FORMULA (I), DONDE D ES (II) EN DONDE K1 Y K4 SON INDEPENDIENTEMENTE -CH2-, -CHR7a-, -CR7b7c-; K2 Y K3 SON INDEPENDIENTEMENTE -CH2-, -CHR8a-, -CR8b8c- O UN GRUPO -C(O); ENTRE OTROS; X ES O, S, SULFONA, ENTRE OTROS; A1 ES N O CR10; A2 ES N O CR11; A3 ES N O CR12; R3 ES H O ALQUILO(C1-C3); R4 Y R5 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; M ES UN TIOFENO DE FORMULA (III) DONDE R2 ES H, HALOGENO, ENTRE OTROS; R6 ES H, HALOGENO, ALQUILO(C1-C2) O AMINO. SON PREFERIDOS: AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-CICLOPENTAN-3-TERC.-BUTOXI-1-CABOXILICO, AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-CICLOPENTAN-3-HIDROXI-1-CARBOXILICO, AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-5-HIDROXI-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-TETRAHIDROFURAN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS TIENEN UN AFECTO ANTITROMBOTICO Y UN EFECTO INHIBIDOR DEL FACTOR Xa, Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES TROMBOTICAS VENOSAS Y ARTERIALES, EMBOLIA PULMONAR, TROMBOSIS CORONARIA
PE2006000745A 2005-06-30 2006-06-27 GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa PE20070171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30

Publications (1)

Publication Number Publication Date
PE20070171A1 true PE20070171A1 (es) 2007-03-08

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000745A PE20070171A1 (es) 2005-06-30 2006-06-27 GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa

Country Status (33)

Country Link
US (3) US20100216769A1 (es)
EP (1) EP1899330B9 (es)
JP (1) JP4768016B2 (es)
KR (1) KR101321722B1 (es)
CN (1) CN101213195B (es)
AR (1) AR054627A1 (es)
AT (1) ATE489381T1 (es)
AU (1) AU2006265216B2 (es)
BR (1) BRPI0612580A8 (es)
CA (1) CA2613059C (es)
CY (1) CY1111627T1 (es)
DE (1) DE502006008392D1 (es)
DK (1) DK1899330T3 (es)
EA (1) EA015188B1 (es)
EC (1) ECSP078058A (es)
ES (1) ES2357029T3 (es)
HK (1) HK1116190A1 (es)
HR (1) HRP20110044T2 (es)
IL (1) IL188323A (es)
MX (1) MX2007016253A (es)
MY (1) MY145883A (es)
NO (1) NO340670B1 (es)
NZ (1) NZ565440A (es)
PE (1) PE20070171A1 (es)
PL (1) PL1899330T3 (es)
PT (1) PT1899330E (es)
RS (1) RS51572B (es)
SG (1) SG163540A1 (es)
SI (1) SI1899330T1 (es)
TW (1) TWI392495B (es)
UA (1) UA94910C2 (es)
WO (1) WO2007003536A1 (es)
ZA (1) ZA200708525B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5002460B2 (ja) 2004-10-04 2012-08-15 ミレニアム ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼインヒビターとして有用なラクタム化合物
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US20090312306A1 (en) * 2006-07-20 2009-12-17 Guangri Sun Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
US8741890B2 (en) * 2007-11-15 2014-06-03 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US7998952B2 (en) 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
WO2010095766A1 (en) * 2009-02-17 2010-08-26 Banyu Pharmaceutical Co.,Ltd. 1,4-benzodiazepin-2-on derivatives
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CA2849434A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
EP4309653A1 (en) * 2014-02-07 2024-01-24 Exithera Pharmaceuticals Inc. Therapeutic compounds and compositions
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
AU2019297402A1 (en) 2018-07-05 2021-01-21 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
PE20221486A1 (es) 2019-12-20 2022-09-26 Bayer Ag Tieniloxazolonas y analogos
WO2022096542A1 (en) 2020-11-06 2022-05-12 Boehringer Ingelheim International Gmbh 2-[thiophen-2-yl)formamido]-n-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192132B1 (en) 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1307203A4 (en) * 2000-03-21 2005-08-17 Smithkline Beecham Corp PROTEINASE INHIBITOR
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040157828A1 (en) 2001-05-17 2004-08-12 Ren Xie Protease inhibitors
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
TW200420559A (en) 2002-11-19 2004-10-16 Takeda Chemical Industries Ltd Amine compounds and method for producing the same
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
WO2005111014A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
EP1748997A1 (de) 2004-05-13 2007-02-07 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
RU2006143842A (ru) 2004-05-13 2008-08-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые замещенные тиофенкарбоксамиды, их получение и их применение в качестве лекарственных средств
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
TWI392495B (zh) 2013-04-11
CY1111627T1 (el) 2015-10-07
ECSP078058A (es) 2008-01-23
RS51572B (en) 2011-08-31
PT1899330E (pt) 2011-01-11
CN101213195A (zh) 2008-07-02
CA2613059C (en) 2013-12-24
BRPI0612580A2 (pt) 2010-11-23
KR20080033318A (ko) 2008-04-16
NO340670B1 (no) 2017-05-29
HK1116190A1 (en) 2008-12-19
ES2357029T3 (es) 2011-04-15
ZA200708525B (en) 2009-08-26
TW200738692A (en) 2007-10-16
US20100216769A1 (en) 2010-08-26
NO20075186L (no) 2008-02-14
SI1899330T1 (sl) 2011-03-31
IL188323A (en) 2013-08-29
JP2008546741A (ja) 2008-12-25
US20150252050A1 (en) 2015-09-10
MY145883A (en) 2012-05-15
IL188323A0 (en) 2008-04-13
PL1899330T3 (pl) 2011-05-31
EP1899330B9 (de) 2011-11-09
BRPI0612580A8 (pt) 2017-12-26
US9676781B2 (en) 2017-06-13
SG163540A1 (en) 2010-08-30
HRP20110044T2 (hr) 2012-02-29
DE502006008392D1 (de) 2011-01-05
UA94910C2 (ru) 2011-06-25
EA015188B1 (ru) 2011-06-30
ATE489381T1 (de) 2010-12-15
EA200702620A1 (ru) 2008-06-30
KR101321722B1 (ko) 2013-10-25
NZ565440A (en) 2011-04-29
CA2613059A1 (en) 2007-01-11
DK1899330T3 (da) 2011-02-21
EP1899330B1 (de) 2010-11-24
JP4768016B2 (ja) 2011-09-07
EP1899330A1 (de) 2008-03-19
AU2006265216A1 (en) 2007-01-11
US9062034B2 (en) 2015-06-23
US20130184256A1 (en) 2013-07-18
AR054627A1 (es) 2007-07-04
WO2007003536A1 (de) 2007-01-11
HRP20110044T1 (en) 2011-02-28
MX2007016253A (es) 2008-03-07
AU2006265216B2 (en) 2011-09-29
CN101213195B (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
PE20070171A1 (es) GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
PE20120330A1 (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
PE20091065A1 (es) Derivados bis-(sulfonilamino) en terapia 066
PE20121806A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
CO5580771A2 (es) Antagonistas ccr5 como agentes terapeuticos
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PE20110118A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
SK116796A3 (en) Cyclic peptide derivative, method for the preparation thereof, the use, and pharmaceutical composition containing the same
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
ECSP088738A (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias
AR023837A1 (es) 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
NO20052307L (no) Blandinger og fremgangsmater for a modifisere toksiske effekter av proteinlignende forbindelser.
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
PE34297A1 (es) Ligandos especificos del neuropeptido y1
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
AR061598A1 (es) Nitroderivados heterociclicos como antagonistas de receptor de endotelina
PE20081473A1 (es) Derivados de piridina como inhibidores de pai-1

Legal Events

Date Code Title Description
FC Refusal